Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
Users online: 2282  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page

Table of Contents 
Year : 2015  |  Volume : 60  |  Issue : 3  |  Page : 307-308
Amifostine before radiotherapy: A rare cause of SJS-TEN overlap

Department of Dermatology, KPC Medical College and Hospital, 1F, Raja SC Mallik Road, Kolkata, West Bengal, - 700 032, India

Date of Web Publication6-May-2015

Correspondence Address:
Sujata Sengupta
Department of Dermatology, KPC Medical College and Hospital, 1F, Raja SC Mallik Road, Kolkata, West Bengal, - 700 032
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5154.156397

Rights and Permissions

How to cite this article:
Sengupta S. Amifostine before radiotherapy: A rare cause of SJS-TEN overlap. Indian J Dermatol 2015;60:307-8

How to cite this URL:
Sengupta S. Amifostine before radiotherapy: A rare cause of SJS-TEN overlap. Indian J Dermatol [serial online] 2015 [cited 2022 Sep 25];60:307-8. Available from:


Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are dermatological emergencies and involvement of 10-30% of BSA is designated as SJS-TEN overlap. Amifostine is a phosphorylated aminothiol prodrug that is US-FDA approved for head and neck cancer, as a prevention of radiotherapy-induced mucositis. It selectively protects the non-affected tissues from radio and chemotherapy-induced toxicities by free radical scavenging. [1]

A 40-year-old man with a non-resectable tumor of the tongue was advised primary radiotherapy (RT). Thirty minutes before each RT session, intravenous amifostine was infused, 200 mg/m 2 per day. He also received IV normal saline, ondansetron, dexamethasone and fluconazole. After the third week of radiation, (RT fraction 30Gy), he developed generalized pruritus with erythematous skin lesions and severe mucositis. Suspecting a drug reaction, RT and all other drugs were stopped and he recovered after 10 days. When only RT with amifostine was resumed, he developed fever, bilateral conjunctivitis, mucosal ulcers and a widespread erythematous macular skin eruption [Figure 1]. SJS-TEN overlap was diagnosed and confirmed by a skin biopsy [Figure 2] and [Figure 3]. RT and amifostine were stopped. He was treated conservatively in the intensive therapy unit with a 5-day dose of methyl prednisolone and topical medications and he slowly recovered 1 month later. After another month, only radiotherapy was resumed without any adverse events.
Figure 1: Skin and mucocutaneous lesions after renewal of RT

Click here to view
Figure 2: Subepidermal cleft formation in a punch biopsy from back (H and E, ×10)

Click here to view
Figure 3: Necrotic keratinocytes (H and E, ×40)

Click here to view

Since after recovery from SJS-TEN, RT without amifostine could be continued without any adverse events, we are convinced that the SJS-TEN can be attributed to amifostine. Hypotension and vomiting with amifostine have been recorded to be more common than skin reactions. The earliest report linking amifostine with SJS-TEN was published in 2000. [2] But a recent study of erythema multiforme, SJS and TEN in patients undergoing radiotherapy showed amifostine to be the second most common drug associated with radiotherapy and these reactions, next only to anticonvulsants. [3] It may also be worth mentioning here that while SJS-TEN overlap may be treated with systemic corticosteroids in these scenarios, their use in denovo TEN remains controversial and has legal implications as well.

Literature search did not reveal any Indian case report that implicated amifostine as a cause of SJS, TEN or SJS-TEN overlap. [4],[5] Patients undergoing radiotherapy are at a considerable risk of developing acute and chronic radiation dermatitis. So, dermatologists are usually quick to diagnose radiation dermatitis. But as amifostine is increasingly being used with RT, we should also be thoroughly equipped to diagnose and deal with life-threatening drug reactions like SJS and TEN.

   References Top

Demiral AN, Yerebakan O, Simºir V, Alpsoy E. Amifostine-induced toxic epidermal necrolysis during radiotherapy: A case report. Jpn J Clin Oncol 2002;32:477-9.  Back to cited text no. 1
Lale Atahan I, Ozyar E, Sahin S, Yildiz F, Yalçin B, Karaduman A. Two cases of Stevens-Johnson syndrome: Toxic epidermal necrolysis possibly induced by amifostine during radiotherapy. Br J Dermatol 2000;143:1072-3.  Back to cited text no. 2
Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, stevens johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: A literature review. Am J Clin Oncol 2014;37:506-13.  Back to cited text no. 3
Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: A multicentric retrospective study. J Postgrad Med 2011;57:115-9.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
Sanmarkan AD, Sori T, Thappa DM, Jaisankar TJ. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis over a period of 10 years. Indian J Dermatol 2011;56:25-9.  Back to cited text no. 5
[PUBMED]  Medknow Journal  


  [Figure 1], [Figure 2], [Figure 3]


Print this article  Email this article
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (986 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    Article Figures

 Article Access Statistics
    PDF Downloaded47    
    Comments [Add]    

Recommend this journal